Standard Research Article
Psychother Psychosom Received: September 27, 2019
DOI: 10.1159/000505600 Accepted: December 23, 2019
Published online: February 18, 2020
Nurse-Guided Internet-Delivered Cognitive
Behavioral Therapy for Insomnia in General
Practice: Results from a Pragmatic Randomized
Clinical Trial
Tanja Van der Zweerdea Jaap Lanceeb, c Pauline Slottjed Judith E. Bosmanse
Eus J.W. Van Somerenf, g Annemieke van Stratena
aDepartment of Clinical Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit, Amsterdam,
The Netherlands; bDepartment of Clinical Psychology, University of Amsterdam, Amsterdam, The Netherlands;
cPsyQ Amsterdam, Amsterdam, The Netherlands; dDepartment of General Practice and Elderly Care, Academic
Network of General Practice (ANH), Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit
Amsterdam, Amsterdam, The Netherlands; eDepartment of Health Sciences, Faculty of Science, Amsterdam Public
Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; fDepartment of Sleep and
Cognition, Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and
Sciences, Amsterdam, The Netherlands; gDepartments of Integrative Neurophysiology and Psychiatry, Centre for
Neurogenomics and Cognitive Research, VU University Medical Centre, Amsterdam, The Netherlands
Keywords Depression Scale), fatigue, daytime consequences of insom-
Cognitive behavioral therapy, nurse-guided · General nia, sleep medication and adverse events. Results: Two
practice · Insomnia · Internet interventions · Sleep disorder thirds of the 69 intervention patients (n = 47; 68%) complet-
ed the whole intervention. At the posttest examination,
there were large significant effects for insomnia severity (Co-
Abstract hen’s d = 1.66), several sleep diary variables (wake after sleep
Introduction: Guidelines recommend cognitive behavioral onset, number of awakenings, terminal wakefulness, sleep
therapy for insomnia (CBT-I) as the first line of treatment for efficiency, sleep quality) and depression. At 26 weeks there
insomnia in general practice, but CBT-I is rarely available. were still significant effects on insomnia severity (d = 1.02)
Nurse-guided Internet-delivered CBT-I might be a solution and on total sleep time and sleep efficiency. No significant
to improve access to care. Objective: We aimed to determine effects were observed for anxiety, fatigue, daily functioning
the effectiveness of nurse-guided Internet-delivered CBT-I or sleep medication. No adverse events were reported. Con-
(I-CBT-I) on insomnia severity experienced by patients in clusions: Nurse-guided I-CBT-I effectively reduces insomnia
general practice. Methods: Nurse-guided I-CBT-I (“i-Sleep”) severity among general practice patients. I-CBT-I enables
was compared to care-as-usual (and I-CBT-I after 6 months) general practitioners to offer effective insomnia care in ac-
in 15 participating general practices among 134 patients cordance with the clinical guidelines.
( 18 years old) with clinical insomnia symptoms. Assess- © 2020 The Author(s)
≥
ments took place at 8, 26 and 52 weeks. Primary outcome Published by S. Karger AG, Basel
was self-reported insomnia severity (Insomnia Severity In-
dex) at 8 weeks. Secondary outcomes were sleep diary indi-
Trial registration: Netherlands Trial register NTR 5202 (April 17, 2015),
ces, depression and anxiety symptoms (Hospital Anxiety and http://www.trialregister.nl.
© 2020 The Author(s) Dr. Tanja van der Zweerde
Published by S. Karger AG, Basel Department of Clinical Psychology, Faculty of Behavior and Movement Sciences
VU University, Van der Boechorststraat 7
karger@karger.com This article is licensed under the Creative Commons Attribution-
www.karger.com/pps NonCommercial-NoDerivatives 4.0 International License (CC BY- NL–1081 BT Amsterdam (The Netherlands)
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). t.vander.zweerde @ vu.nl
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Introduction mild mental health symptoms. They vary in their back-
ground and training but most often they are either mental
With prevalence rates between 7 and 10% in the gen- health nurses or recently graduated psychologists. In this
eral population [1], clinical insomnia is the second most study we refer to them as “nurses.” The nurses delivered
prevalent mental disorder [2]. In general practice, fatigue the I-CBT-I and provided online feedback. We opted for
and sleeplessness are respectively the first and third most nurse practitioners because not enough trained psycholo-
reported complaints, and insomnia is estimated to occur gists are available in the Netherlands. More importantly,
in as many as 30% of general practice patients [1, 3]. In- in the Dutch health care system, patients who are referred
somnia leads to a high disease burden on its own but also to a psychologist because of insomnia have to pay for
increases the risks of developing other psychiatric prob- treatment out of pocket. The care provided by nurses in
lems [4, 5] and cardiovascular diseases [6]. Insomnia, and general practice falls under the GP care and is fully reim-
its comorbid problems, leads to high societal costs, main- bursed. Therefore, this is more feasible for offering in-
ly due to productivity losses [7, 8]. somnia treatment to patients.
Cognitive behavioral treatment for insomnia (CBT-I) The primary objective of this pragmatic randomized
is an evidence-based treatment with large effects on in- controlled trial was to assess whether nurse-guided I-
somnia severity (demonstrated in several meta-analyses, CBT-I is effective in routine general practice compared
e.g. Hedges’ g = 0.98 [9]). CBT-I is recommended by (in- to care as usual (CAU) on insomnia severity. Second-
ter)national guidelines [10–13] as the first treatment op- arily, sleep diary indices, mental health complaints and
tion for insomnia. In general practice, somewhat smaller daily functioning were assessed. Effects were studied im-
effects are reported, but still in the moderate range (Hedg- mediately after treatment (posttest; 8 weeks), after 26
es’ g = 0.40 [14]). Despite these moderate effects and the weeks and (in the intervention group only) after 52
guideline recommendations, sleep medication is still the weeks.
most commonly used treatment in general practice: 60%
of new insomnia patients generally only receive medica-
tion [15]. Even though general practitioners (GPs) ac- Material and Methods
knowledge the importance of CBT-I, they lack the time
Research Design
and/or knowledge to offer it themselves and there is a lack
This 2-arm, pragmatic randomized clinical trial compared I-
of CBT-I trained therapists to refer to [16]. Internet-de-
CBT-I to CAU. Patients in the intervention group were also al-
livered CBT-I (I-CBT-I) presents a promising way to in-
lowed to receive CAU. Patients in the control group received the
crease the availability of CBT-I and to enable GPs to ad- intervention after the 26-week assessment if they still wanted it.
here to insomnia guideline recommendations. Randomization charts were made for each nurse separately, us-
ing random sequence block randomization (blocks of 2, 4 or 6)
Internet treatments usually consist of a number of les-
on a 1:1 ratio and stratified by sleep medication use. Participants
sons in which an evidence-based intervention is ex-
were randomized using randomization charts created by an in-
plained. This might be text-based, video-based or a mix-
dependent researcher. A second independent researcher per-
ture. Another core feature is that patients receive assign- formed the randomization. The primary researcher (T.Z.) was
ments. They need to apply techniques they read about in blinded to treatment allocation. After allocation, the primary re-
searcher, participants, nurses and GPs were informed of the ran-
the online lessons to their own daily lives. The treatment
domization outcome. Participants in CAU were informed they
might be offered without any support, but we know that
would be offered I-CBT-I after 6 months. GPs strongly requested
the adherence and effects are better when it is offered with
also being informed when patients were randomized to CAU so
some type of support [17]. In general, guided Internet they could offer other treatments and patients would not be left
treatments seem as effective as face-to-face treatments on their own. The Medical Ethics Committee of the VU Medical
Centre Amsterdam approved this trial (registration No.
[18], and this is also demonstrated for I-CBT-I [19, 20].
2015/258), and it was registered with the Dutch Trial Registry
However, these results are mostly based on self-selected,
(NTR5202, April 17, 2015). The detailed protocol is available
specifically recruited online samples of help seekers [19, elsewhere [22].
21]. It is not known whether I-CBT-I also works among
patients in a routine general practice. This is what we Power
In the original protocol we calculated our power based on an
want to examine in the current study.
independent t test. To ensure 80% statistical power with a 2-sided
In the Netherlands almost all GPs employ a mental
α-value of 0.05, assuming a conservative effect size of Cohen’s d =
health nurse practitioner. Those nurse practitioners pro- 0.50 on the primary outcome insomnia severity [23] and expecting
vide psychosocial support or treatment for people with a risk of 20% dropout [24], we aimed to include 160 participants.
2 Psychother Psychosom Van der Zweerde/Lancee/Slottje/
DOI: 10.1159/000505600 Bosmans/Van Someren/van Straten
CONSORT 2010 Flow Diagram
Assessed for eligibility (n = 262)
Enrollment Excluded (n = 44)
♦ Not a patient with a participating
GP (n = 10)
♦ Not meeting DSM-5 criteria
(n = 22)
• Shift work (n = 7)
• Schizophrenia/psychosis (n = 2)
• Already in psych. treatment (n = 2)
• No Dutch (n = 1)
• Apnea (n = 6)
Randomized (n = 134) • Other reasons (n = 1)
Allocation
Allocated to intervention (n = 69) Allocated to CAU waitlist
♦Received allocated intervention (n = 69) (n = 65)
Completed all 5 sessions (n = 47)
Completed 3 sessions (n = 3)
Completed 2 sessions (n = 6)
Completed 1 session (n = 5)
Completed 0 sessions (n = 8)
Follow-up
Lost to follow-up (give reasons) Lost to follow-up (give reasons)
Posttest (T1) Posttest (T1)
- questionnaires: n = 43 (62%) - questionnaires: n = 41 (63%)
- sleep diaries: n = 55 (80%) - sleep diaries: n = 50 (77%)
Follow-up (T2) Follow-up (T2)
- questionnaires: n = 35 (51%) - questionnaires: n = 37 (57%)
- sleep diaries: n = 47 (68%) - sleep diaries: n = 45 (69%)
Analysis
Analyzed (n = 69) Analyzed (n = 65)
♦ Excluded from analysis ♦ Excluded from analysis
(give reasons) (give reasons)
Fig. 1. CONSORT flowchart of participant flow throughout the trial.
When we analyzed the data, we decided it was more appropriate plain it to patients, to use during consultations. Additionally, GPs
to employ a statistical procedure taking baseline levels into ac- sent invitation letters and leaflets to patients who had consulted
count. Based on this within-between group analysis and the them for insomnia in the past year. All recruitment materials re-
achieved sample size (n = 134), we obtained a power of 0.8 (α = ferred patients to our study website which explained the study in
0.05) to detect an effect size of d = 0.24. more detail. Patients could leave their e-mail address to show that
they were interested. They then received an e-mail with a link to a
Recruitment screening questionnaire. Eligible patients received all information
Recruitment leaflets were distributed in print and on screens in in printed form, a sleep diary, informed consent form and stamped
waiting rooms. GPs and nurses were asked to alert all possible eli- return envelope. Patients were randomized after returning the
gible insomnia patients who consulted them to the trial. GPs and completed sleep diary and informed consent. The inclusion period
nurses received laminated summaries of the trial and how to ex- was extended from originally 18 months to 30 months. We ended
Internet-Delivered CBT-I in General Psychother Psychosom 3
Practice: A Randomized Controlled Trial DOI: 10.1159/000505600
enilno
elbaliava
noisrev
roloC
inclusion in April 2018, at 134 of the planned 160 participants for Intervention
pragmatic reasons (Fig. 1 for a flow chart).1 The i-Sleep intervention was developed by the first, second and
last authors and is based on CBT-I [29–33]. i-Sleep consists of 5
Eligibility Criteria lessons. Each lesson consists of information which is offered in text
Inclusion criteria were: (1) 18 years or older; (2) reporting lying format as well as video. Furthermore, every lesson includes a ficti-
awake for 30 min a night for 3 nights per week for 3 months; tious and a real-life case example (also in text format and video).
≥ ≥ ≥
and (3) causing clinically significant distress or impairment in dai- After every lesson the patient needs to fill out “homework” (sleep
ly functioning. The duration and frequency of insomnia com- diary and e.g. setting bedtimes). Lesson 1 focused on psychoeduca-
plaints were assessed in an online screening questionnaire. The tion about healthy and disordered sleep and sleep hygiene. In les-
consequences during the day were assessed with the Daytime Con- son 2, stimulus control is introduced (getting out of bed when
sequences items [25]. This scale assesses 6 domains of function- awake for >15 min, using the bed for sleep and sexual activity only)
ing: energy, relationships, mood, concentration, productivity and and patients start sleep restriction therapy. Lesson 3 teaches relax-
sleepiness. Each domain was measured using a 5-point Likert scale ation and minimizing worrying. Lesson 4 is aimed at tackling dys-
(0 = not disturbed, 4 = very disturbed). We defined daytime con- functional cognitions about sleep. The fifth and final lesson invites
sequence as scoring at least a 3 on one of the domains. These inclu- the participant to make a summary of lessons learned and con-
sion criteria (sleep complaints and consequences for daily func- struct a relapse prevention plan.
tioning) were chosen because they resemble the DSM-5 criteria for Participants were advised to complete one lesson per week and
an insomnia disorder [26]. Exclusion criteria were: (1) no access to received online coaching from the nurse in their own general prac-
the Internet; (2) inadequate proficiency in Dutch; (3) meeting tice. The aim of the feedback was to motivate patients to carry on,
sleep apnea criteria; (4) pregnancy or breastfeeding; (5) working to offer explanations if needed and to comment on the completed
night shifts; (6) other current psychological treatment; (7) suicidal exercises. Patients had the possibility to ask the nurses additional
ideation or (8) schizophrenia or psychotic disorder. In order to questions (online). Nurses received approximately 1.5 h of training
identify sleep apnea, we used the Screening for Sleeping Disorders from the first author (T.Z.) on how to guide i-Sleep and back-
questionnaire [27]. Patients with a positive score for suspected un- ground knowledge about sleep and treatment. Every nurse first
treated sleep apnea (reporting snoring, breathing stops and exces- treated a mock patient under supervision (T.Z.), using the feedback
sive daytime sleepiness) were excluded. Suicidal ideation over the manual created for this trial. Further supervision was offered on an
past month was assessed using 5 MINI diagnostic interview items as-needed basis, assessed by regular phone calls and e-mail contact
in the self-report screening questionnaire (e.g., thoughts about sui- (T.Z.). Nurses reported spending between 5 and 20 min per patient
cide, making plans or attempting suicide) [28]. Patients in both per session on providing online feedback. Feedback was program-
groups were allowed to use sleep medication and over-the-counter prompted: all participants received feedback on all completed ses-
sleep aids without restrictions. sions. The intervention did not include face-to-face contact and
was provided at no cost to participants. Intervention group par-
General Practices ticipants were free to receive other GP care as needed. The i-Sleep
At first, we recruited general practices through the Academic intervention is not primarily aimed at tapering or discontinuing
Network of General Practices (n = 8). This is a structural collabo- medication but does discuss the (dis)advantages of medication. Pa-
ration between a number of general practices in the Amsterdam tients are advised to contact their GP if they want to reduce or quit.
area and the department of General Practice at Amsterdam Uni- A previous study has shown that the i-Sleep intervention is effective
versity Medical Centre. Due to low inclusion rates, we sought ad- among insomnia patients recruited in the general population [21].
ditional practices outside Amsterdam during the trial (n = 7).
There were around 50 GPs working in the 15 participating gen- CAU Control Condition
eral practices. GPs participating in this study received a printed version of the
The GP practices employed mental health nurses with either a most recent Dutch insomnia guidelines for GPs [10] to promote a
university degree in psychology (62%) or higher vocational train- similar knowledge level on guidelines among participating prac-
ing as a psychiatric nurse (38%). Their average age was 51 (SD = tices. We did not otherwise interfere with CAU as offered by GPs.
11, range 32–64 years) Their clinical experience ranged from 6 We reported to GPs which patients were randomized to CAU and
months to 15 years (mean = 6.9 years, SD = 5). Most of them re- invited these participants to use i-Sleep 6 months after randomiza-
ported some experience with e-Health (77%), 8% reported little tion.
experience and 15% no experience.
Measurements
1 Due to the low inclusion rates and difficulty reaching our envisioned sam- Timing of the Assessments
ple size, we made several changes to the protocol along the course of the Assessment took place at baseline (week 0), after treatment
trial. First, we changed an exclusion criterion. Originally, the protocol was (week 8), at 26 weeks and 52 weeks. After the third assessment (26
to exclude patients who had psychological treatment (for insomnia or other weeks), the CAU patients were offered the i-Sleep treatment (n =
complaints) in the past 6 months. We switched to excluding only patients in 37 [57%] accepted). The 52-week follow-up is uncontrolled. This
current psychological treatment. Patients previously excluded for this reason follow-up aimed to determine whether effects in the intervention
(n = 3) were invited to participate again (of whom 2 did). Second, we initially
group are sustained over time.
recruited only patients who consulted their GP for insomnia prospectively.
We switched to GPs actively screening electronic medical records and invit-
Primary Outcome Measures
ing all patients who had consulted their GP in the last year to our screening
questionnaire. Third, we dropped actigraphy measures early on in the trial The primary outcome measure was the Insomnia Severity In-
because these led to considerable logistic difficulties. dex [34] (ISI; range 0–28). The ISI contains 7 items scored on a
4 Psychother Psychosom Van der Zweerde/Lancee/Slottje/
DOI: 10.1159/000505600 Bosmans/Van Someren/van Straten
5-point Likert scale (0 = not at all, 4 = extremely). The ISI is a reli- Statistical Analysis
able instrument possessing adequate internal consistency (Cron- We performed intent-to-treat analyses (i.e., on all 134 included
bach’s α = 0.90 [35]) and was validated for online use [36]. Clini- participants, irrespective of whether treatment was completed)
cally significant improvement is defined as a change of 8 points, [42]. We performed generalized mixed multilevel (patient and
≥
a clinical cutoff of ISI >10 is used to define patients with clinical condition) regression analysis to evaluate the effects of time (with-
insomnia symptoms [35]. in-group), condition (between-group) and the interaction be-
tween time × condition (between-group). For normally distribut-
Secondary Outcome Measures ed outcomes regular linear mixed regressions using identity links
We used a pen-and-paper version of the Dutch translation of were used, and mixed negative binomial regression analyses with
the Carney consensus diary [37] to estimate several sleep charac- a log link otherwise. To assess differences in change in outcomes
teristics: sleep onset latency (SOL; number of minutes it takes to between the two conditions, we performed a series of two-level
fall asleep), sleep efficiency (SE; 0–100%; total sleep time divided (participants and time points) repeated-measures analyses in two
by the total time in bed), number of awakenings (NWAK), wake separate models: one to assess change in outcome from pre- to
after sleep onset (WASO; total minutes awake after sleep onset), posttest assessment and one assessing change in outcomes from
terminal wakefulness (TWAK; time spent awake in bed before get- pre- to 26 weeks follow-up. Assuming data were missing at ran-
ting up), total sleep time (TST) and sleep quality (SQ; rated 1–5 dom, we applied an unstructured covariance matrix as most fitting
each night). Participants completed 7-day diaries at each assess- to the data [43]. Baseline characteristics significantly predicting
ment, aggregated into week averages for analysis. Diaries with at dropout were added to the model as covariates (daytime conse-
least 5 days completed were included in the analysis. quences and sex). Baseline differences between the two conditions
We used the 14-item Hospital Anxiety and Depression Scale to were not tested for statistical significance [44]. Between-group Co-
assess anxiety and depression [38, 39]. Each item is scored on a hen’s d effect sizes were calculated by calculating the pre-post
scale of 0–3, and the total scores thus range from 0 to 21 for both change scores for both groups and calculating the difference. We
the Anxiety and the Depression scales. then divided these by the pooled standard deviations observed at
Daytime functioning (energy, relationships, mood, concentra- baseline [45].
tion, productivity and sleepiness) was measured using a 5-point We also compared the percentage of patients recovered (ISI
scale (0–4; range 0–24) for each of the 6 items of the Daytime Con- below clinical cutoff of 11) or showing clinically significant im-
sequences items [25]. We used the Work and Social Adjustment provement on the primary outcome (ISI; defined as a change of 8
≥
Scale to measure 4 domains of functioning (household tasks, work points) [35] between the intervention and control group at posttest
productivity, close relationships and social life) [40]. Each domain examination and at 26 weeks follow-up. For the uncontrolled 52-
is measured on a scale of 0–8. Fatigue was measured with the Fa- week follow-up, within-group effect sizes were calculated based on
tigue Severity Scale [41] which consists of 7 items (scored 1–7). The observed means. For all statistical analyses, the two-sided signifi-
total score ranges from 7 (no fatigue) to 49 (severely fatigued). cance level was set at p < 0.05. Data were analyzed using SPSS for
Finally, we assessed the use of sleep medication and antidepres- Windows 25.
sant use. These data were collected both by direct reporting by
participants and by examining the electronic medical records of Changes to Protocol
the participants, separately. Due to privacy regulations we could We made two changes to our original protocol [22] both with
not cross-check the medication use and therefore we report on the intention to enhance recruitment. In the original protocol the
both self-report (at the different assessments) and GP records recruitment strategy was described as GPs inviting patients during
(covering the complete inclusion period). From GP records we a face-to-face consultation for sleep problems. We added a direct
extracted whether patients had received at least one prescription mailing of all patients who had consulted the GP for sleep prob-
during the assessment period (between baseline and follow-up at lems in the last year. Furthermore, in the original protocol we de-
26 weeks) of benzodiazepine derivatives (N05CD, N05BA), ben- scribed that we would exclude patients who received prior or cur-
zodiazepine-related drugs (N05CF) or antidepressants (N06A), rent psychological treatment. We changed this to excluding pa-
using the Anatomical Therapeutic Chemical classification of the tients only for current, not prior, psychological treatment.
World Health Organization (www.whocc.no/atc). From these re-
cords we could not determine whether a patient’s use had declined
over the course of the trial, hence we additionally asked patients to
report medication use at all assessments (“Have you used sleep Results
medication in the past 4 weeks?” – yes/no).
Participants were asked to report (minor) falls, traffic accidents
Participants
and other adverse events (“Did anything unpleasant happen to you
The final sample consisted of 134 adults, randomized
that was related to your sleep or participation in the trial?”) at each
assessment. If yes, they were asked to describe what happened and to i-Sleep (n = 69) or the CAU control group (n = 65;
whether any medical or psychological assistance was needed.2 Fig. 1 for a flowchart).3 The mean age was 50.6 (SD =
2 We did not report on data on alcohol use as per protocol due to a technical
error in the data collection procedure that led to a lot of missing data. One 3 Further details on the analysis are available from the first author (i.e., tables
of the originally 5 items of the Work and Social Adjustment Scale is miss- with regression coefficients, observed means and observed within-group ef-
ing for the same reason (we report on the other 4 and not on a total score). fect sizes).
Internet-Delivered CBT-I in General Psychother Psychosom 5
Practice: A Randomized Controlled Trial DOI: 10.1159/000505600
Table 1. Characteristics of the sample at baseline
Characteristic i-Sleep Control 22
(n = 69) (n = 65)
20
Age, years 51.7 (15.77) 49.4 (16.01) 18
Female sex 43 (62%) 44 (68%)
Higher education1 53 (77%) 39 (60%) 16
Born in the Netherlands 60 (87%) 56 (86%) 14
Living situation
Alone 22 (32%) 29 (45%) 12
Married/living together 45 (65%) 31 (48%)
10
Other 2 (3%) 5 (7%)
Living with children 22 (32%) 15 (23%) 8
Pre Post
Paid job or own company 48 (70%) 45 (69%)
Prescribed sleep medication use 23 (33%) 25 (39%)
Previous psychological treatment
(any) 13 (19%) 16 (25%)
Data expressed as means (standard deviation) or numbers (%).
1 Higher, higher vocational or university education.
15.9), 65% of the sample was female and 87% was born in to posttest assessment, F = 29.62, p < 0.001, d =
1, 88 between
the Netherlands (Table 1). In the i-Sleep condition, 47 1.66 and from pre-examination to follow-up at 26 weeks,
participants (68%) completed the intervention, and 22 F = 10.65, p = 0.002, d = 1.02 (Fig. 2). This indi-
1, 74 between
(32%) did not (8 did not start and 14 dropped out during cates that I-CBT-I resulted in participants experiencing a
treatment). The study response rate (providing data) was greater improvement in insomnia severity than CAU pa-
83% (n = 111) at the posttest assessment, 80% (n = 107) tients from pre- to postassessment and from preassess-
at 26 weeks and 62% (n = 43, intervention group only) at ment to 26-week follow-up. See Table 2 for confidence
52 weeks. Contributions to data did not differ significant- intervals. The intervention group more often reported a
ly between conditions (8 weeks: χ2 = 0.28, p = 0.60; 26- clinically significant improvement (improvement on ISI
week follow-up: χ2 = 0.817, p = 0.37). At baseline, the av- score 8 points) than patients in the control group at the
≥
erage insomnia score (ISI = 18.9) refers to moderate clin- posttest assessment (56 vs. 12%) and at 26 weeks (46 vs.
ical levels of insomnia. There were no patients without 11%; Table 3).
insomnia (as defined by ISI scores <11), 17 patients (13%)
reported subthreshold clinical insomnia (ISI <14), 80 re- Secondary Outcomes: Effect on Sleep Diary Indices
ported moderate-severe (60%; ISI 15–21) and 37 reported Multilevel regression analyses showed significant
severe insomnia (28%; ISI 22–28). At baseline, sleep med- time × condition interaction effects at the posttest assess-
ication was used by 33% (i-Sleep group) versus 39% (con- ment for the sleep diary variables: WASO, F = 14.09,
1, 94
trol group) of the participants. The average score on anx- p < 0.001, d = 0.54; NWAK, F = 11.32, p
between 1, 102 ≤
iety was 8.16 which indicates subclinical levels of anxiety 0.001, d = 0.43; TWAK, F = 5.84, p = 0.018,
between 1, 96
(>11 indicative of anxiety disorder) [38]. The average d = 0.31; SQ, F = 5.23, p = 0.025, d = 0.52
between 1, 90 between
score on depression was 6.21 which indicates subclinical and SE, F = 17.23, p < 0.001, d = 0.61. This in-
1, 112 between
levels of depression (>11 indicative of depressive disor- dicates that participants in the i-Sleep condition showed
der) [38]. Of all patients, 20 (15%) scored above the anx- more improvement on time spent awake in bed and sleep
iety cutoff, and 13 patients (10%) scored above the de- efficiency than patients receiving CAU at the posttest as-
pression cutoff [39]. sessment. No significant differences were observed for
SOL, TST or sleep quality. At 26 weeks of follow-up, sig-
Primary Outcome: Effect on ISI nificant interaction effects of time × condition were ob-
Multilevel regression analyses showed significant served for SE, F = 5.55, p = 0.02, d = 0.41, and
1, 103 between
time × condition interaction effects for the ISI, from pre- TST, F = 5.89, p = 0.017, d = 0.41 (Table 2).
1, 99 between
6 Psychother Psychosom Van der Zweerde/Lancee/Slottje/
DOI: 10.1159/000505600 Bosmans/Van Someren/van Straten
erocs
ISI
CBT-I
CAU
FU
Fig. 2. Insomnia Severity Index (ISI) estimated means for intent-
to-treat analysis from baseline (pre) to posttest assessment and
from baseline to 26-week and 52-week follow-up (FU).
Table 2. Multilevel intention-to-treat regression based pre-, post- and follow-up (FU) estimates and Cohen’s d effect sizes
Measure Group Pre-post model-estimated mean score Pre-FU model-estimated mean score Between Significance2 Between Significance
(StE) (StE) Cohen’s d1 Cohen’s d
effect size: effect size:
Pre Post Pre Post pre to post pre to FU
ISI i-Sleep 19.12 (0.42) 11.04 (0.81) 19.26 (0.44) 12.73 (0.88) 1.66 p < 0.001 1.02 p = 0.002
CAU 18.74 (0.47) 16.99 (0.74) 18.85 (0.46) 16.20 (0.81)
SOL i-Sleep 46.99 (4.15) 31.41 (3.10) 47.37 (4.01) 36.17 (3.56) 0.22 p = 0.099 0.21 p = 0.190
CAU 45.89 (5.60) 39.67 (4.10) 44.71 (5.58) 42.51 (5.31)
WASO i-Sleep 54.98 (4.86) 30.25 (4.22) 55.61 (5.08) 33.90 (4.76) 0.54 p < 0.001 0.10 p = 0.435
CAU 57.39 (6.13) 56.92 (6.84) 57.01 (5.87) 39.85 (5.30)
NWAK i-Sleep 1.27 (0.15) 0.85 (0.13) 1.28 (0.15) 0.98 (0.16) 0.43 p = 0.001 0.10 p = 0.575
CAU 1.15 (0.15) 1.23 (0.16) 1.15 (0.15) 0.97 (0.15)
TWAK i-Sleep 45.67 (3.23) 25.59 (3.05) 45.78 (3.15) 30.32 (4.45) 0.31 p = 0.018 0.28 p = 0.121
CAU 42.99 (4.27) 33.92 (3.76) 43.93 (4.44) 38.55 (5.20)
TST i-Sleep 341.41 (6.63) 372.49 (7.61) 339.60 (6.74) 382.02 (7.11) 0.23 p = 0.122 0.41 p = 0.017
CAU 357.04 (8.17) 372.66 (9.35) 354.87 (8.06) 369.97 (9.94)
SE i-Sleep 66.84 (1.40) 77.64 (1.33) 66.37 (1.42) 76.26 (1.56) 0.61 p < 0.001 0.41 p = 0.020
CAU 68.86 (1.68) 71.59 (1.83) 68.59 (1.72) 73.08 (2.05)
Sleep quality i-Sleep 2.50 (0.07) 2.87 (0.07) 2.53 (0.08) 3.11 (0.08) 0.52 p = 0.025 0.40 p = 0.103
CAU 2.65 (0.07) 2.71 (0.10) 2.67 (0.07) 3.01 (0.11)
Daytime cons. i-Sleep 18.62 (0.42) 16.04 (0.59) 18.66 (0.43) 16.18 (0.61) 0.39 p = 0.123 0.26 p = 0.248
CAU 19.81 (0.41) 18.55 (0.53) 19.87 (0.41) 18.26 (0.50)
HADS-A i-Sleep 8.47 (0.37) 7.55 (0.44) 8.41 (0.36) 7.54 (0.43) 0.19 p = 0.275 0.15 p = 0.309
CAU 8.07 (0.36) 7.70 (0.43) 7.92 (0.35) 7.49 (0.37)
HADS-D i-Sleep 6.13 (0.35) 4.59 (0.50) 6.10 (0.38) 4.50 (0.50) 0.37 p = 0.024 0.21 p = 0.154
CAU 5.85 (0.48) 5.77 (0.46) 5.78 (0.48) 5.00 (0.45)
Fatigue (FSS) i-Sleep 39.51 (0.83) 33.76 (1.27) 39.54 (0.83) 33.60 (1.46) 0.08 p = 0.641 0.10 p = 0.567
CAU 40.39 (1.14) 35.45 (1.49) 40.48 (1.13) 33.53 (1.49)
WSAS: household i-Sleep 3.66 (0.23) 2.72 (0.29) 3.53 (0.22) 3.22 (0.26) 0.32 p = 0.108 0.03 p = 0.879
CAU 4.20 (0.25) 3.92 (0.27) 4.07 (0.25) 3.70 (0.33)
WSAS: work productivity i-Sleep 4.51 (0.18) 2.84 (0.28) 4.46 (0.18) 3.63 (0.32) 0.38 p = 0.097 0.09 p = 0.714
CAU 4.54 (0.22) 3.58 (0.25) 4.50 (0.23) 3.50 (0.30)
WSAS: close relationships i-Sleep 3.86 (0.21) 2.90 (0.29) 3.76 (0.21) 3.42 (0.33) 0.21 p = 0.247 0.11 p = 0.609
CAU 3.99 (0.24) 3.46 (0.24) 3.91 (0.23) 3.35 (0.26)
WSAS: social life i-Sleep 4.26 (0.22) 3.08 (0.28) 4.14 (0.23) 3.51 (0.32) 0.36 p = 0.052 0.02 p = 0.939
CAU 4.11 (0.23) 3.69 (0.24) 4.02 (0.23) 3.43 (0.26)
DC, daytime consequences; FU, follow-up; FSS, Fatigue Severity Scale; HADS-A, Hospital Anxiety and Depression Scale – anxiety subscale; i-Sleep, i-Sleep treatment condition; ISI, Insomnia Severity Index;
NWAK, number of awakenings; SE, sleep efficiency; SOL, sleep onset latency; StE, standard error; TST, total sleep time; TWAK, terminal wakefulness; WASO, wake after sleep onset; WSAS, work and social adjustment
scale. 1 Computed by dividing the difference in posttest scores by the pooled observed standard deviations at baseline; a Cohen’s d is commonly considered to be either small (i.e. <0.20), moderate (around 0.50) or
large (0.80 and over; Cohen [23]). Negative effect sizes indicate negative changes (i.e., higher severity of complaints, or CAU outperforming i-Sleep condition for between-groups effect size). 2 Significance levels
derived from multilevel regression analyses.
Table 3. χ2 tests of differences in clinical improvement on observed insomnia severity at posttest (8 weeks), 26-week and 52-week follow-
up assessments
Post FU 26 weeks FU 52 weeks
recovered clin. significantly recovered clin. significantly recovered clin. significantly
(ISI <11) improved (ISI <11) improved (ISI <11) improved
(∆ISI ≥8) (∆ISI ≥8) (∆ISI ≥8)
i-Sleep 28 (65%) 24 (56%) 15 (43%) 16 (46%) 18 (45%) 16 (40%)
CAU 2 (5%) 5 (12%) 3 (8%) 4 (11%) n.a. n.a.
χ2 33.2 17.7 11.6 10.9 n.a. n.a.
p < 0.001. FU, fo**ll*ow-up; CAU, ca*r*e* as usual; ISI, Insom*n*ia* Severity Index;* n**.a., not available.
***
Secondary Outcomes: Effect on Mood, Anxiety, ment for depression, F = 5.28, p = 0.024, d = 0.37,
1, 103 between
Fatigue and Daily Functioning but no statistically significant time × condition effects on
Multilevel regression analyses showed a significant anxiety, fatigue, daytime consequences or daily function-
time × condition interaction effect at the posttest assess- ing (Work and Social Adjustment Scale items: household
Internet-Delivered CBT-I in General Psychother Psychosom 7
Practice: A Randomized Controlled Trial DOI: 10.1159/000505600
tasks, work productivity, close relationships and social SE). No significant effects were observed on the other sec-
life). At 26 weeks of follow-up, no significant interaction ondary outcomes, anxiety, fatigue, daytime consequences
effects were observed for any of the secondary outcomes. or sleep medication.
Both conditions improved significantly over time on these Our aim was to test whether I-CBT-I’s effects would
measures of mental health and daytime functioning. stand the test in a general practice population. One of our
hypotheses was that patients actively seeking help from
Secondary Outcomes: Medication their GP would be different than those who respond to
There were no significant differences in sleep medica- online advertisement for insomnia treatment. However,
tion use, as reported by patients themselves, between the when comparing the baseline scores of our population to
intervention and CAU group at baseline (33 vs. 39%, p = those of other studies among the general population we
0.54) or at the posttest assessment (20 vs. 23% p = 0.96). do not see many differences. The participants in our trial
At the 26-week follow-up, twice as many patients in the were suffering from relatively severe insomnia (mean
control group used medication (29%) than in the inter- baseline ISI score 18.9 in our sample) but the same is the
vention group (13%). However, this difference is not sta- case in, for example, the online study of Kaldo et al. [46]
tistically significant (p = 0.75). At the 52-week follow-up, (baseline ISI score 16.8) or Lancee et al. [47] (baseline ISI
10 i-Sleep participants (23%) used sleep medication. GP score 18.2). Baseline sleep efficiency (66% in our trial) was
records showed that over the complete trial period 30% also very similar to the ones reported by Kaldo et al. [46]
used sleep medication (25% benzodiazepine derivatives, (71%) and Lancee et al. [47] (64%). Furthermore, 15% of
5% Z drugs) in the i-Sleep condition versus 47% of the our population scored above the cutoff on our anxiety
control group (40% benzodiazepine derivatives, 7% Z questionnaire and 10% did so for depression. This also
drugs). Antidepressants were used by 12% of i-Sleep par- seems to indicate that our population did not suffer sub-
ticipants over this period, versus 25% in the control group. stantially more often from comorbid mental disorders
than those who are recruited in the general population.
One-Year Uncontrolled Follow-Up All this does not necessarily mean that people who ac-
Within-group effect sizes in the i-Sleep condition in- tively seek help are similar to those who do not. They
dicate that the effects were sustained at 52 weeks of fol- might be different on aspects we did not measure, e.g. the
low-up (d ranging from 1.69 [ISI] to 0.23 [SOL]); extent of social support, or their personality traits. It is
within
however, the response rate at 52 weeks of follow-up was important that we showed that I-CBT-I can be effectively
quite low (62%). delivered in general practice because in many countries
the GP functions as a gatekeeper and is the first person to
Adverse Events go to when looking for help for insomnia. This online in-
No serious adverse events (warranting psychological tervention enables GPs to offer insomnia care according
or medical care) were reported. At the posttest assess- to the current clinical guidelines. Support costs relatively
ment, one CAU participant mentioned a surgery for un- little time (on average 1.5 h per patient) and does not have
related medical reasons. to be delivered by highly trained (psychological) profes-
sionals but can be offered by people with a higher voca-
tional background after a short training: in this case sup-
Discussion port was effectively executed by the nurses employed in
the general practice.
This pragmatic randomized controlled trial showed We included not only sleep outcomes, but also other rel-
that nurse-guided I-CBT-I is effective in general practice evant secondary outcomes. Surprisingly, on many of these
in reducing insomnia symptoms. The study showed that indices no effect of I-CBT-I was observed, a finding only
I-CBT-I is feasible and can be used in general practice partly in line with other trials. For instance, CBT-I often
with support from nurses. The intervention yielded large also has beneficial effects for depression and anxiety com-
effect sizes compared to CAU on insomnia severity (d = plaints [48–50]. We were able to replicate the effect at the
1.66 after treatment, and d = 1.02 after 26 weeks). These posttest assessment for depressive complaints but this was
effects remained at the 52-week follow-up. We also dem- no longer detected at the 26-week follow-up. The relatively
onstrated significant secondary effects at the posttest as- low level of severity of depression in our sample might ex-
sessment (sleep diary WASO, NWAK, TWAK, SQ, and plain the lack of mental health effects. Our sample may have
depressive symptoms) and 26-week follow-up (TST and consisted of people with an isolated insomnia problem not
8 Psychother Psychosom Van der Zweerde/Lancee/Slottje/
DOI: 10.1159/000505600 Bosmans/Van Someren/van Straten
(yet) generalized to other areas of mental health (i.e., only treatment or by offering it in a blended way (online and
10% suffered from depression). Our participants did show face-to-face sessions). This might depend on the individ-
considerable baseline impairments in daytime functioning. ual patients’ motivation and other characteristics. Anoth-
Most studies observe improvements in daytime function- er strong feature is our high assessment response rate
ing after insomnia treatment [20, 25]. We did not find a (Fig. 1). About 80% completed the posttest measurement.
significant effect but the effect sizes for the various domains A limitation of our study is the slow inclusion rate and
of functioning are between d = 0.21 and d = 0.39. A possible the early termination of inclusion before we reached our
explanation for the lack of significance is that the study was desired sample size which has consequences for the pow-
underpowered to detect these clinically relevant effects, al- er of the secondary analyses in particular. The low inclu-
though by adding baseline measurements to the analysis we sion rate was partly due to time and resource constraints
have likely increased power [51]. in general practice. Although the participating GPs and
It remains difficult to understand that the intervention nurses were highly motivated and enthusiastic about hav-
showed large effects on insomnia but not on fatigue. Fa- ing an alternative treatment to offer insomnia patients
tigue is one of the most frequently reported symptoms of other than or in addition to medication, the trial was not
patients seeking help from insomnia. However, a recent always mentioned during (insomnia-related) GP consul-
meta-analysis into the effect of insomnia treatments on tations which may have lowered inclusion rates. GP
fatigue also concludes that there is no effect [50]. Impor- awareness and involvement should be a strong focus
tantly, this meta-analysis indicates that there is a high het- point in future research. An additional limitation is that
erogeneity between studies indicating that some are more polysomnographic measurements were not feasible in
successful than others. At the moment, the association be- this research setting. Although we deem subjective mea-
tween sleep and fatigue is still poorly understood. We def- sures of this psychological problem to be most important,
initely need more research to uncover the (un)shared as is reflected by the DSM-5 nosology [26], it would have
mechanisms. Network intervention analysis could be used been valuable to have polysomnographic data in addi-
in order to shed light on the treatment effects on individ- tion. We aimed to include actigraphy data, but unfortu-
ual symptoms, since insomnia, fatigue and daytime symp- nately this also turned out not to be feasible. The research
tom questionnaires are prone to overlap somewhat [52]. context likely influenced uptake as well. Patients may
The assessments of sleep medication and antidepres- have been hesitant to take part in a trial and could be more
sant use were complicated, due to the combination of self- willing to undergo I-CBT-I through their GP outside of
report and GP data which we could not link. Moreover, a the research setting. A related limitation is the use of a
prescription is not necessarily the same as usage. Using a CAU control condition [54]. We had expected that GPs
more reliable measure (such as sophisticated bottle cap would have provided more care (e.g., medication, sleep
chips counting numbers of pills taken) was not feasible in hygiene advice, referral to a psychologist or physiothera-
this trial. Even though there are no significant differences, pist) since we explicitly handed over the most recent in-
both the GP data and the self-report data indicate less use somnia guidelines and notified the GPs of the patients
of sleep medication (and antidepressants) in the interven- who were randomized to the control group. However, it
tion group than in the control group. At 26 weeks the turned out that most patients in the control group did not
control group reports more than twice (29%) as much receive much care and started i-Sleep after the waiting
sleep medication use than the intervention group (13%), period. The control group thus resembled a waitlist con-
which is a promising result which needs to be replicated dition which may have induced a nocebo effect [55].
in larger trials. Previous research has indeed indicated In summary, we reached our goal of offering GPs a
that CBT-I can have favorable effects on sleep medication time-efficient treatment that is highly effective in reduc-
use and can facilitate the discontinuation process [53]. ing insomnia complaints. A cost-effectiveness analysis of
Our trial has several strong features. First of all, that it the intervention will be a valuable next step, as would
was a pragmatic trial. We showed that it is feasible to im- comparing the intervention to an unguided version of-
plement an I-CBT-I treatment in routine GP care. Fur- fered in general practice. This might increase uptake since
thermore, we showed that the treatment is acceptable for it requires even less work by GPs and nurses, but it may
patients. A large majority (68%) completed the treatment decrease adherence and have a lower effect [17]. We dem-
fully, which is higher than often observed in online treat- onstrated the potential of I-CBT-I in routine general
ment for insomnia [24]. Adherence might even be raised practice: i-Sleep clearly outperformed CAU on insomnia
by adding a face-to-face session before the start of the severity and several sleep diary indices in this trial. The
Internet-Delivered CBT-I in General Psychother Psychosom 9
Practice: A Randomized Controlled Trial DOI: 10.1159/000505600
large effects on insomnia severity are important towards Disclosure Statement
prevention of mental health problems for which insom-
J.E.B., E.J.W.S. and P.S. have no conflicts of interest to declare.
nia is a risk factor as well [4]. Although further research
A.S., J.L. and T.Z. have developed the online treatment and made
is needed to illuminate potential effects on other mental
the book version available online (PDF) and in print, but have no
health complaints and daily functioning and the longer- commercial interests.
term effects of online interventions [56], we recommend
GPs to implement nurse-guided I-CBT-I as a way of al-
leviating insomnia symptoms through feasible, effective, Funding Sources
guideline adherent treatment.
The trial was funded by ZonMW (project No.: 837002504).
Acknowledgments
Author Contributions
We thank all participating patients, GPs and nurses for their
time and effort. T.Z., A.S., J.L., E.J.W.S. and P.S. contributed to the design of the
study. A.S. and J.L. wrote the i-Sleep treatment manual. T.Z. devel-
oped the Internet-delivered i-Sleep intervention. T.Z. carried out re-
cruitment and data collection, supervised the treatment delivery and
Statement of Ethics
provided the guidance for control participants after the controlled
phase of the trial. T.Z. performed the statistical analysis and drafted
The authors assert that all procedures contributing to this work
the manuscript. All authors contributed to and approved the paper.
comply with the ethical standards of the relevant national and in-
stitutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008.
References
1 Ohayon MM. Epidemiology of insomnia: 8 Daley M, Morin CM, LeBlanc M, Grégoire JP, 14 Cheung JM, Jarrin DC, Ballot O, Bharwani
what we know and what we still need to learn. Savard J, Baillargeon L. Insomnia and its rela- AA, Morin CM. A systematic review of cogni-
Sleep Med Rev. 2002 Apr;6(2):97–111. tionship to health-care utilization, work ab- tive behavioral therapy for insomnia imple-
2 Wittchen HU, Jacobi F, Rehm J, Gustavsson senteeism, productivity and accidents. Sleep mented in primary care and community set-
A, Svensson M, Jönsson B, et al. The size and Med. 2009b Apr;10(4):427–38. tings. Sleep Med Rev. 2019 Apr;44:23–36.
burden of mental disorders and other disor- 9 Van Straten A, van der Zweerde T, Kleiboer 15 Hoebert J, Souverein P, Mantel-Teeuwisse
ders of the brain in Europe 2010. Eur Neuro- A, Cuijpers P, Morin CM, Lancee J. Cognitive AK, Leufkens HG, van Dijk L. Benzodiazepi-
psychopharmacol. 2011 Sep;21(9):655–79. and behavioral therapies in the treatment of negebruik daalt als de gebruiker zelf betaalt.
3 Van der Linden MW, Westert GP, de Bakker insomnia: a meta-analysis. Sleep Med Rev. Huisarts Wet. 2012 Jul;55(7):286–8.
DH, Schellevis FG. Tweede Nationale Studie 2018 Apr;38:3–16. 16 Everitt H, McDermott L, Leydon G, Yules H,
naar ziekten en verrichtingen in de huis- 10 NHG-werkgroep Slaapproblemen en slaap- Baldwin D, Little P. GPs’ management strate-
artspraktijk. Klachten en aandoeningen in de middelen. NHG-Standaard Slaapproblemen gies for patients with insomnia: a survey and
bevolking en in de huisartspraktijk. Utrecht, en slaapmiddelen (tweede herziening). Huis- qualitative interview study. Br J Gen Pract.
Bilthoven: NIVEL/RIVM; 2004. arts Wet. 2014;57:352–61. 2014 Feb;64(619):e112–9.
4 Li MJ, Kechter A, Olmstead RE, Irwin MR, 11 National Institute for Clinical Excellence. 17 Lancee J, van den Bout J, Sorbi MJ, van Straten
Black DS. Sleep and mood in older adults: co- Guidance on the use of zaleplon, zolpidem A. Motivational support provided via email
inciding changes in insomnia and depression and zopiclone for the short-term manage- improves the effectiveness of internet-deliv-
symptoms. Int Psychogeriatr. 2018 Mar; ment of insomnia. Technology Appraisal ered self-help treatment for insomnia: a ran-
30(3):431–5. Guidance [TA77]. London: NICE; 2004. domized trial. Behav Res Ther. 2013 Dec;
5 Olfson M, Wall M, Liu SM, Morin CM, Blan- 12 Qaseem A, Kansagara D, Forciea MA, Cooke 51(12):797–805.
co C. Insomnia and Impaired Quality of Life M, Denberg TD; Clinical Guidelines Com- 18 Andersson G, Cuijpers P, Carlbring P, Riper
in the United States. J Clin Psychiatry. 2018 mittee of the American College of Physicians. H, Hedman E. Guided Internet-based vs.
Sep;79(5):17m12020. Management of chronic insomnia disorder in face-to-face cognitive behavior therapy for
6 Sofi F, Cesari F, Casini A, Macchi C, Abbate adults: a clinical practice guideline from the psychiatric and somatic disorders: a system-
R, Gensini GF. Insomnia and risk of cardio- American College of Physicians. Ann Intern atic review and meta-analysis. World Psychi-
vascular disease: a meta-analysis. Eur J Prev Med. 2016 Jul;165(2):125–33. atry. 2014 Oct;13(3):288–95.
Cardiol. 2014 Jan;21(1):57–64. 13 Riemann D, Baglioni C, Bassetti C, Bjorvatn 19 Zachariae R, Lyby MS, Ritterband LM,
7 Daley M, Morin CM, LeBlanc M, Grégoire JP, B, Dolenc Groselj L, Ellis JG, et al. European O’Toole MS. Efficacy of internet-delivered
Savard J. The economic burden of insomnia: guideline for the diagnosis and treatment of cognitive-behavioral therapy for insomnia: a
direct and indirect costs for individuals with in- insomnia. J Sleep Res. 2017 Dec;26(6):675– systematic review and meta-analysis of ran-
somnia syndrome, insomnia symptoms, and 700. domized controlled trials. Sleep Med Rev.
good sleepers. Sleep. 2009a Jan;32(1):55–64. 2016 Dec;30:1–10.
10 Psychother Psychosom Van der Zweerde/Lancee/Slottje/
DOI: 10.1159/000505600 Bosmans/Van Someren/van Straten
20 Espie CA, Emsley R, Kyle SD, Gordon C, 31 Edinger JD, Means MK. Cognitive-behavioral 46 Kaldo V, Jernelöv S, Blom K, Ljótsson B, Bro-
Drake CL, Siriwardena AN, et al. Effect of dig- therapy for primary insomnia. Clin Psychol din M, Jörgensen M, et al. Guided internet
ital cognitive behavioral therapy for insomnia Rev. 2005 Jul;25(5):539–58. cognitive behavioral therapy for insomnia
on health, psychological well-being, and 32 Verbeek I, Klip E. Insomnia. Amsterdam: compared to a control treatment: a random-
sleep-related quality of life: a randomized Boom Uitgevers; 2005. ized trial. Behav Res Ther. 2015 Aug;71:90–
clinical trial. JAMA Psychiat. 2019 Jan;76(1): 33 Espie C. Overcoming Insomnia and Sleep 100.
21-30. Problems: A Self-help Guide using Cognitive 47 Lancee J, van Straten A, Morina N, Kaldo V,
21 van Straten A, Emmelkamp J, de Wit J, Lancee Behavioral Techniques. London: Robinson; Kamphuis JH. Guided online or face-to-face
J, Andersson G, van Someren EJ, et al. Guid- 2006. cognitive behavioral treatment for insomnia:
ed Internet-delivered cognitive behavioural 34 Bastien CH, Vallières A, Morin CM. Valida- a randomized wait-list controlled trial. Sleep
treatment for insomnia: a randomized trial. tion of the Insomnia Severity Index as an out- (Basel). 2016 Jan;39(1):183–91.
Psychol Med. 2014 May;44(7):1521–32. come measure for insomnia research. Sleep 48 van der Zweerde T, van Straten A, Effting M,
22 Van der Zweerde T, Lancee J, Slottje P, Bos- Med. 2001 Jul;2(4):297–307. Kyle SD, Lancee J. Does online insomnia
mans J, Van Someren E, Reynolds C 3rd, et al. 35 Morin CM, Belleville G, Bélanger L, Ivers H. treatment reduce depressive symptoms? A
Cost-effectiveness of i-Sleep, a guided online The Insomnia Severity Index: psychometric randomized controlled trial in individuals
CBT intervention, for patients with insomnia indicators to detect insomnia cases and evalu- with both insomnia and depressive symp-
in general practice: protocol of a pragmatic ate treatment response. Sleep (Basel). 2011 toms. Psychol Med. 2019 Feb;49(3):501–9.
randomized controlled trial. BMC Psychiatry. May;34(5):601–8. 49 Ye YY, Zhang YF, Chen J, Liu J, Li XJ, Liu YZ,
2016 Apr;16(Dec):85. 36 Thorndike FP, Ritterband LM, Saylor DK, et al. Internet-based cognitive behavioral
23 Cohen J. Statistical Power Analysis for the Be- Magee JC, Gonder-Frederick LA, Morin CM. therapy for insomnia (ICBT-i) improves co-
havioral Sciences. 2nd ed. New York: Law- Validation of the insomnia severity index as a morbid anxiety and depression—a meta-
rence Erlbaum Associates; 1988. web-based measure. Behav Sleep Med. 2011; analysis of randomized controlled trials. PLoS
24 Horsch C, Lancee J, Beun RJ, Neerincx MA, 9(4):216–23. One. 2015 Nov;10(11):e0142258.
Brinkman WP. Adherence to technology-me- 37 Carney CE, Buysse DJ, Ancoli-Israel S, Eding- 50 Ballesio A, Aquino MR, Feige B, Johann AF,
diated insomnia treatment: a meta-analysis, er JD, Krystal AD, Lichstein KL, et al. The Kyle SD, Spiegelhalder K, et al. The effective-
interviews, and focus groups. J Med Internet consensus sleep diary: standardizing prospec- ness of behavioural and cognitive behavioural
Res. 2015 Sep;17(9):e214. tive sleep self-monitoring. Sleep (Basel). 2012 therapies for insomnia on depressive and fa-
25 Espie CA, Kyle SD, Williams C, Ong JC, Feb;35(2):287–302. tigue symptoms: a systematic review and net-
Douglas NJ, Hames P, et al. A randomized, 38 Olssøn I, Mykletun A, Dahl AA. The Hospital work meta-analysis. Sleep Med Rev. 2018 Feb;
placebo-controlled trial of online cognitive Anxiety and Depression Rating Scale: a cross- 37:114–29.
behavioral therapy for chronic insomnia dis- sectional study of psychometrics and case 51 Mazumdar S, Tang G, Houck PR, Dew MA,
order delivered via an automated media-rich finding abilities in general practice. BMC Psy- Begley AE, Scott J, et al. Statistical analysis of
web application. Sleep (Basel). 2012 Jun; chiatry. 2005 Dec;5(1):46. longitudinal psychiatric data with dropouts. J
35(6):769–81. 39 Spinhoven P, Ormel J, Sloekers PP, Kempen Psychiatr Res. 2007 Dec;41(12):1032–41.
26 American Psychiatric Association. Diagnos- GI, Speckens AE, Van Hemert AM. A valida- 52 Blanken TF, Van Der Zweerde T, Van Straten
tic and statistical manual of mental disorders. tion study of the Hospital Anxiety and De- A, Van Someren EJ, Borsboom D, Lancee J.
5th ed. Washington: American Psychiatric pression Scale (HADS) in different groups of Introducing Network Intervention Analysis
Association; 2013. Dutch subjects. Psychol Med. 1997 Mar; to investigate sequential, symptom-specific
27 Wilson SJ, Nutt DJ, Alford C, Argyropoulos 27(2):363–70. treatment effects: A demonstration in co-oc-
SV, Baldwin DS, Bateson AN, et al. British As- 40 Mundt JC, Marks IM, Shear MK, Greist JH. curring insomnia and depression. Psychother
sociation for Psychopharmacology consensus The Work and Social Adjustment Scale: a Psychosom. 2019;88(1):52–4.
statement on evidence-based treatment of in- simple measure of impairment in function- 53 Ong J, Suh S. Utilizing cognitive-behavioral
somnia, parasomnias and circadian rhythm ing. Br J Psychiatry. 2002 May;180(5):461–4. therapy for insomnia to facilitate discontinu-
disorders. J Psychopharmacol. 2010 Nov; 41 Krupp LB, LaRocca NG, Muir-Nash J, Stein- ation of sleep medication in chronic insomnia
24(11):1577–601. berg AD. The fatigue severity scale. Applica- patients. Sleep Med Res. 2012 Aug;3(1):1–6.
28 Sheehan DV, Lecrubier Y, Sheehan KH, tion to patients with multiple sclerosis and 54 Guidi J, Brakemeier EL, Bockting CL, Cosci F,
Amorim P, Janavs J, Weiller E, et al. The systemic lupus erythematosus. Arch Neurol. Cuijpers P, Jarrett RB, et al. Methodological
Mini-International Neuropsychiatric Inter- 1989 Oct;46(10):1121–3. recommendations for trials of psychological
view (M.I.N.I.): the development and valida- 42 Newell DJ. Intention-to-treat analysis: impli- interventions. Psychother Psychosom. 2018;
tion of a structured diagnostic psychiatric in- cations for quantitative and qualitative re- 87(5):276–84.
terview for DSM-IV and ICD-10. J Clin Psy- search. Int J Epidemiol. 1992 Oct;21(5):837– 55 Furukawa TA, Noma H, Caldwell DM, Hon-
chiatry. 1998;59 Suppl 20:22–33. 41. yashiki M, Shinohara K, Imai H, et al. Waiting
29 Edinger JD, Wohlgemuth WK. The signifi- 43 Heck RH, Tabata L, Thomas SL. Multilevel list may be a nocebo condition in psychother-
cance and management of persistent primary and longitudinal modeling with IBM SPSS. apy trials: a contribution from network meta-
insomnia: the past, present and future of be- Abingdon: Routledge; 2013. https://doi. analysis. Acta Psychiatr Scand. 2014 Sep;
havioral insomnia therapies. Sleep Med Rev. org/10.4324/9780203701249. 130(3):181–92.
1999 Jun;3(2):101–18. 44 Twisk JWR, Bosman L, Hoekstra T, Rijnhart 56 Klein NS, Kok GD, Burger H, van Valen E,
30 Morin CM, Espie CA. Insomnia: A Clinical JJM, Welten M, Heijmans M. Different ways Riper H, Cuijpers P, et al. No sustainable ef-
Guide to Assessment and Treatment. New to estimate treatment effects in randomised fects of an Internet-based relapse prevention
York: Kluwer Academic/Plenum Publishers; controlled trials. Contemp Clin Trials Com- program over 24 months in recurrent depres-
2003. mun. 2018 Mar;10:80–5. sion: primary outcomes of a randomized con-
45 Morris SB. Estimating effect sizes from pre- trolled trial. Psychother Psychosom. 2018;
test-posttest-control group designs. Organ 87(1):55–7.
Res Methods. 2008 Apr;11(2):364–86.
Internet-Delivered CBT-I in General Psychother Psychosom 11
Practice: A Randomized Controlled Trial DOI: 10.1159/000505600
